SEC Filing Analysis: Relay Therapeutics, Inc. (RLAY)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A new director, Lonnel Coats, has been appointed to the board of Relay Therapeutics and, as of this initial filing, holds no company securities.
• Market Impact: Neutral. This is a routine corporate governance disclosure.

Company Information

Field	Value
Company	Relay Therapeutics, Inc.
Ticker Symbol	RLAY
CIK	0001812364
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	COATS LONNEL
CIK	0001612528
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	3
Transaction Date	2025-11-04
Transaction Code	null
Security Type	null
Shares Involved	0
Price Per Share	null
Total Value	$0
Shares Owned After	0
Ownership Type	null

Financial Impact Assessment

Transaction Materiality

As this is a Form 3 reporting no initial ownership, there is no financial transaction to assess. All materiality metrics are zero.

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	0
% of Shares Outstanding	0.0%
Post-Transaction Ownership	0 shares (0.0% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market cap of $1.18 billion, any future transactions by the new director will be evaluated against this figure. This initial filing has no financial impact.
• Ownership Concentration: The insider currently holds no shares, so there is no impact on ownership concentration.
• Dilution Impact: Not applicable as there is no issuance of new shares.
• Transaction Significance: The significance of this filing is purely informational, signaling a change in the company's governance structure with the addition of a new board member.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing reports the appointment of a new director and an initial ownership of zero shares. It is a standard administrative disclosure and does not involve any trading activity that would influence market perception.

Volume & Sentiment

• Expected Volume Impact: None. This type of filing does not typically affect trading volume.
• Sentiment Indicator: Neutral. The market sentiment towards RLAY is unlikely to be affected by this routine corporate filing.

Key Takeaways

1. New Director Appointed: Lonnel Coats has joined the Board of Directors of Relay Therapeutics.
2. Initial Ownership Statement: This Form 3 serves as the initial declaration of beneficial ownership as required by the SEC.
3. Zero Shares Held: As of the event date, the new director does not own any shares of Relay Therapeutics, Inc.

Additional Context

Transaction Notes

• Filing Type: A Form 3 is required to be filed within 10 days of an individual becoming a corporate insider (director, officer, or 10%+ owner). The tag <noSecuritiesOwned>1</noSecuritiesOwned> explicitly confirms the insider holds no securities.